Mucoepidermoid Carcinoma (MEC)
Mucoepidermoid carcinoma (MEC) poses a significant challenge as a rare cancer affecting the salivary glands, demanding the development of targeted therapies to enhance outcomes. At our company, we provide a wide array of comprehensive services aimed at contributing to the progress of mucoepidermoid carcinoma (MEC) therapeutic options.
Introduction to Mucoepidermoid Carcinoma (MEC)
Mucoepidermoid carcinoma (MEC) is an uncommon malignancy originating from the secretory cells of the salivary glands. It represents the most prevalent type of cancer affecting both major and minor salivary glands, comprising approximately 30% of all salivary gland tumors. MEC exhibits a diverse spectrum of histological grades and prognoses.
Pathogenesis of Mucoepidermoid Carcinoma (MEC)
The exact cause of mucoepidermoid carcinoma (MEC) remains unknown. However, certain risk factors have been identified, such as exposure to radiation, certain genetic alterations, and viral infections. Studies have shown that MAML2 gene rearrangement is a frequent genetic event in MEC, leading to the activation of the Notch signaling pathway and tumorigenesis.
Fig. 1 Therapeutic strategy for mucoepidermoid carcinoma. (Sama S., et al., 2022)Targets of Mucoepidermoid Carcinoma (MEC) Therapy
To effectively treat mucoepidermoid carcinoma (MEC), it is crucial to identify and target specific therapeutic markers. Several molecular targets have been recognized in MEC, such as the Notch signaling pathway, epidermal growth factor receptor (EGFR), and HER2/neu receptor. Focusing on these pathways and receptors presents a promising avenue for the development of innovative therapeutic approaches. By pinpointing and manipulating these targets, we can potentially enhance the effectiveness of MEC therapeutics and improve outcomes.
Therapies of Mucoepidermoid Carcinoma (MEC)
Chemotherapy
Standard chemotherapy regimens, such as cisplatin plus vinorelbine (VNB), paclitaxel, and docetaxel, have shown moderate activity in treating Mucoepidermoid Carcinoma (MEC). Combination therapy with cisplatin and VNB has demonstrated improved outcomes compared to single-agent therapy.
Monoclonal Antibodies
Monoclonal antibodies, like trastuzumab, target specific receptors like HER2/neu and have shown limited response as single agents. Combining them with other agents can enhance their therapeutic activity.
Targeted Therapies
Targeted therapies, such as sorafenib, nintedanib, lapatinib, ANA-12, and vorinostat, inhibit specific pathways involved in tumor growth and angiogenesis. These therapies have shown promising results in terms of disease control and progression-free survival.
Our Services
At our company, we offer a comprehensive range of diagnostics and therapy development services for mucoepidermoid carcinoma (MEC). Our team of experts conducts extensive research to identify and validate novel therapeutic targets specific to mucoepidermoid carcinoma (MEC). This enables the development of targeted therapies with enhanced efficacy.
Therapy Development Platforms
Animal Models of Mucoepidermoid Carcinoma (MEC)
| Transgenic Model Development | ||
| In the transgenic model, we have employed genetic crossing with MMTV-Cre mice or direct AAV-Cre transduction to induce the expression of the CRTC1-MAML2 fusion gene specifically in salivary glandular cells. As a result, the transgenic mice develop salivary gland tumors that closely resemble the histological characteristics of human MEC. | ||
| Optional Models |
|
|
| Xenograft Model Development | ||
| In addition to transgenic models, our company also offers xenograft model development services for MEC research. Xenograft models involve the transplantation of human MEC c or tissues into immune-compromised mice. | ||
| Optional Models |
|
|
| Optional Species | Mouse, Rat, Non-human primates, Others | |
Furthermore, we offer a wide range of personalized animal models tailored to meet various requirements. If you are interested in our services, please do not hesitate to contact us for further information and details regarding pricing and related services.
Reference
- Sama S., et al. "Advances in the treatment of mucoepidermoid carcinoma." World Journal of Oncology 13.1 (2022): 1.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.